JAC Advance Access originally published online on July 12, 2006
Journal of Antimicrobial Chemotherapy 2006 58(3):680-683; doi:10.1093/jac/dkl283
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus
1 Section of Infectious Diseases, Michael E. Debakey Veterans Affairs Medical Center 2002 Holcombe Boulevard, Houston, TX 77030, USA 2 Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine Houston, TX 77030, USA 3 Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine Houston, TX 77030, USA
Received 23 December 2005; returned 11 May 2006; revised 20 May 2006; accepted 15 June 2006
*Correspondence address. Section of Infectious Diseases (111G), Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030-4211, USA. Tel: +1-713-794-7384; Fax: +1-713-794-7045; E-mail: Daniel.Musher{at}va.gov
Background: The recent proliferation of community-acquired (CA) methicillin-resistant Staphylococcus aureus (MRSA) has led to a marked increase in the need for outpatient treatment of MRSA infections. Many oral agents active against MRSA have been available for years, and a paucity of literature compares them, leaving physicians with little guidance for choosing among them. The purpose of the present study was to compare the bactericidal effects of orally available antibiotics against MRSA and to determine whether there were differences in antimicrobial killing activity against CA-MRSA and hospital-acquired (HA) MRSA isolates.
Methods: A total of 12 unique patient MRSA isolates were studied. Six strains were CA, carrying the staphylococcal chromosomal cassette (SCCmec) type IVa, while six were HA and carried SCCmec type II. Time–kill methods were used to study the bactericidal activity of the orally available antimicrobials linezolid, rifampicin, trimethoprim/sulfamethoxazole, clindamycin, minocycline, and moxifloxacin alone and in combination in vitro.
Results: Trimethoprim/sulfamethoxazole was rapidly bactericidal resulting in >2 log10 cfu/mL decrease at 8 h and >3 log10 cfu/mL decrease at 24 h in vitro. No antibiotic combination exhibited better killing than trimethoprim/sulfamethoxazole alone. Adding rifampicin to trimethoprim/sulfamethoxazole showed a trend towards antagonism in vitro. There were no differences in the bactericidal activity of any antimicrobial or antimicrobial combination against MRSA isolates carrying SCCmec type IVa versus those carrying SCCmec type II.
Conclusion: Trimethoprim/sulfamethoxazole is rapidly bactericidal against MRSA in vitro when compared with most other orally available antimicrobials. No differences in bactericidal activity were detected when activities against CA-MRSA and HA-MRSA were compared.
Keywords: trimethoprim/sulfamethoxazole , linezolid , time–kill , bactrim
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. M. Nguyen and C. J. Graber Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J. Antimicrob. Chemother., October 27, 2009; (2009) dkp377v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Vandecasteele, J. R. Boelaert, and A. S. De Vriese Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1388 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Euba, O. Murillo, N. Fernandez-Sabe, J. Mascaro, J. Cabo, A. Perez, F. Tubau, R. Verdaguer, F. Gudiol, and J. Ariza Long-Term Follow-Up Trial of Oral Rifampin-Cotrimoxazole Combination versus Intravenous Cloxacillin in Treatment of Chronic Staphylococcal Osteomyelitis Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2672 - 2676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Elliott, T. E. Zaoutis, A. B. Troxel, A. Loh, and R. Keren Empiric Antimicrobial Therapy for Pediatric Skin and Soft-Tissue Infections in the Era of Methicillin-Resistant Staphylococcus aureus Pediatrics, June 1, 2009; 123(6): e959 - e966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Murillo, M. E. Pachon, G. Euba, R. Verdaguer, F. Tubau, C. Cabellos, J. Cabo, F. Gudiol, and J. Ariza Antagonistic Effect of Rifampin on the Efficacy of High-Dose Levofloxacin in Staphylococcal Experimental Foreign-Body Infection Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3681 - 3686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Moellering Jr A 39-Year-Old Man With a Skin Infection JAMA, January 2, 2008; 299(1): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hmouda, C. Ben Salem, K. Bouraoui, and L. Jemni Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation Arch Intern Med, June 11, 2007; 167(11): 1207 - 1208. [Full Text] [PDF]
|
|
|
|
|
|
H. Hmouda, C. Ben Salem, K. Bouraoui, and L. Jemni Comment on: Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus J. Antimicrob. Chemother., December 1, 2006; 58(6): 1307 - 1307. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Kaka and D. M. Musher Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus: authors' response J. Antimicrob. Chemother., December 1, 2006; 58(6): 1307 - 1308. [Full Text] [PDF]
|
|